Bio-medicine is certainly an area where the lead time for a technology can be twice to thrice than that in IC due to human trials and animal trials. But the advances have more impact than that of IC on human as in one case we only improve the quality of life while in other we save lives.
Seems to be a 60,000ft-level view of what is possible using BioMEMS while the engineer in me is screaming for more details!
For one, I would like to know how the diffusion or osmotic layers (for exchange/purification of hemoflow in dialysis) are fabricated in the microchannels of MEMS. Driven by electrophoretic process, one still needs such a membrane layer to 'process' the fluids in the application described above.
Most of the microfluidic devices (like lab-on-a-chip) that are in use today are for DNA analysis or chemical assay. I certainly welcome the application in BioMEMS if they can make the lives of those who need better at lower cost.
Dr. MP Divakar
It is wonderful that the technology now exists to make things smaller than needed - because that then enables the desired scale to be assembled. With recent developments including solar cell chargers that fit inside the eye and artificial vision systems that bypass defective retinal cells to directly access the optic nerve, we may be on the brink of a number of manmade replacement organs.
As we unveil EE Times’ 2015 Silicon 60 list, journalist & Silicon 60 researcher Peter Clarke hosts a conversation on startups in the electronics industry. Panelists Dan Armbrust (investment firm Silicon Catalyst), Andrew Kau (venture capital firm Walden International), and Stan Boland (successful serial entrepreneur, former CEO of Neul, Icera) join in the live debate.